Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humira sBLA Submitted For Ankylosing Spondylitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott filed a supplemental BLA with FDA seeking approval of the TNF-inhibitor Humira (adalimumab) as a treatment for ankylosing spondylitis Oct. 4
Advertisement

Related Content

Humira To Compete With Remicade, Enbrel in Ankylosing Spondylitis
Humira To Compete With Remicade, Enbrel in Ankylosing Spondylitis
Abbott Anticipates Humira sBLA For Crohn’s Disease By Year-End
Abbott Anticipates Humira sBLA For Crohn’s Disease By Year-End
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis

Topics

Advertisement
UsernamePublicRestriction

Register

PS061206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel